William Hageman

771 citations

33 papers · 610 indexed · h-index 13

Organic Chemistry top 10%
Molecular Biology
Pharmacology top 10%
Computational Theory and Mathematics top 10%
Pharmacology

Co-authors: John A. Masucci Gary W. Caldwell Zhengyin Yan David M. Ritchie John B. Moore Bruce E. Maryanoff Keith T. Demarest Sigmond G. Johnson
Topics: Neuroendocrine regulation and behavior (6 papers)Pharmacogenetics and Drug Metabolism (5 papers)Electrolyte and hormonal disorders (4 papers)
Cited by: Pharmacology Organic Chemistry Pharmaceutical Science
Journals: Journal of the American Chemical Society Analytical Biochemistry Journal of Medicinal Chemistry
Partner nations: United States Germany Israel

In The Last Decade

William Hageman

32 papers receiving 570 citations

Peers

Countries citing papers authored by William Hageman

Since Specialization

Citations

This map shows the geographic impact of William Hageman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Hageman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Hageman more than expected).

Fields of papers citing papers by William Hageman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Hageman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Hageman. The network helps show where William Hageman may publish in the future.

Co-authorship network of co-authors of William Hageman

This figure shows the co-authorship network connecting the top 25 collaborators of William Hageman. A scholar is included among the top collaborators of William Hageman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Hageman. William Hageman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Improved Pharmacokinetic and Bioavailability Support of Drug Discovery Using Serial Blood Sampling in Mice 2008 ·Journal of Pharmaceutical Sciences ·Sean Peng,(unknown),(unknown),Norman Huebert,William Hageman	39
2	CHARACTERIZATION OF RWJ‐351647, A NOVEL NONPEPTIDE VASOPRESSIN V₂RECEPTOR ANTAGONIST 2006 ·Clinical and Experimental Pharmacology and Physiology ·Joseph W. Gunnet,Jay M. Matthews,Bruce E. Maryanoff,Lawrence de Garavilla,Patricia Andrade‐Gordon,Bruce P. Damiano,William Hageman,Richard Look,(unknown),Anthony J. Streeter,(unknown),Keith T. Demarest	8
3	The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens 2005 ·European Journal of Drug Metabolism and Pharmacokinetics ·Gary W. Caldwell,David M. Ritchie,John A. Masucci,William Hageman,(unknown),(unknown),(unknown),William J. Jones	9
4	The application of nuclear magnetic resonance-based metabonomics to the dominant–submissive rat behavioral model 2005 ·Analytical Biochemistry ·Gregory C. Leo,Gary W. Caldwell,Jeffrey J. Crooke,Ewa Malatyńska,(unknown),(unknown),(unknown),(unknown),(unknown),William Hageman	3
5	Pyrazinobenzodiazepines as Potent Nonpeptide Vasopressin Receptor Antagonists 2005 ·Letters in Drug Design & Discovery ·Jay M. Matthews,Dennis J. Hlasta,Patricia Andrade‐Gordon,Keith T. Demarest,(unknown),Joseph W. Gunnet,William Hageman,Richard Look,John B. Moore,Bruce E. Maryanoff	5
6	1,2,3,4-Tetrahydroquinoline-containing αVβ3 integrin antagonists with enhanced oral bioavailability 2004 ·Bioorganic & Medicinal Chemistry Letters ·Shyamali Ghosh,Rosemary J. Santulli,William A. Kinney,(unknown),Li Liu,(unknown),(unknown),Gregory C. Leo,John A. Masucci,William Hageman,Andrew S. Thompson,Ian Chen,Reiko Kawahama,Robert W. Tuman,Robert A. Galemmo,Dana L. Johnson,Bruce P. Damiano,Bruce E. Maryanoff	13
7	Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists 2004 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Robert H. Chen,Keith T. Demarest,Joseph W. Gunnet,Richard Look,William Hageman,William V. Murray,Donald W. Combs,Philip J. Rybczynski,Mona Patel	4
8	Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists 2004 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Robert H. Chen,Keith T. Demarest,Joseph W. Gunnet,Richard Look,William Hageman,William V. Murray,Donald W. Combs,Mona Patel	10
9	Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates 2004 ·Bioorganic & Medicinal Chemistry Letters ·Jay M. Matthews,William J. Hoekstra,Alexey B. Dyatkin,Leonard R. Hecker,Dennis J. Hlasta,(unknown),Patricia Andrade‐Gordon,Lawrence de Garavilla,Keith T. Demarest,(unknown),Joseph W. Gunnet,William Hageman,Richard Look,John B. Moore,Charles H. Reynolds,Bruce E. Maryanoff	17
10	Discovery of a dihydropyrimidine series of molecules that selectively mimic the biological actions of calcitonin 2004 ·Bioorganic & Medicinal Chemistry Letters ·Jay M. Matthews,(unknown),William Hageman,Ralph A. Rivero,Lori Westover,Maria Yang,Jun Xu,Keith T. Demarest	10
11	Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists 2003 ·Bioorganic & Medicinal Chemistry Letters ·Jay M. Matthews,Michael N. Greco,Leonard R. Hecker,William J. Hoekstra,Patricia Andrade‐Gordon,Lawrence de Garavilla,Keith T. Demarest,(unknown),Joseph W. Gunnet,William Hageman,Richard Look,John B. Moore,Bruce E. Maryanoff	30
12	Bridged bicyclic vasopressin receptor antagonists with V2-Selective or dual V1a/V2 activity 2002 ·Bioorganic & Medicinal Chemistry Letters ·Alexey B. Dyatkin,William J. Hoekstra,Dennis J. Hlasta,Patricia Andrade‐Gordon,Lawrence de Garavilla,Keith T. Demarest,Joseph W. Gunnet,William Hageman,Richard Look,Bruce E. Maryanoff	10
13	The New Pre-Preclinical Paradigm: Compound Optimization in Early and Late Phase Drug Discovery 2001 ·Current Topics in Medicinal Chemistry ·Gary W. Caldwell,David M. Ritchie,John A. Masucci,William Hageman,Zhengyin Yan	102
14	Synthesis and 5-Lipoxygenase Inhibitory Activities of Some Novel 2-Substituted 5-Benzofuran Hydroxamic Acids 1994 ·Journal of Medicinal Chemistry ·Kwasi A. Ohemeng,(unknown),Van N. Nguyen,Charles F. Schwender,Monica Singer,(unknown),Justin Ansell,Dennis Argentieri,William Hageman	41
15	Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid 1992 ·Journal of Medicinal Chemistry ·Michael N. Greco,William Hageman,(unknown),(unknown),(unknown)	17
16	Antinociceptive action of McN-5195 in rodents: a structurally novel (indolizine) analgesic with a nonopioid mechanism of action. 1990 ·Journal of Pharmacology and Experimental Therapeutics ·Jeffry L. Vaught,John R. Carson,(unknown),Paul S. Blum,(unknown),William Hageman,Richard P. Shank,Robert B. Raffa	27
17	Inhibition of Leukotriene and Thromboxane Biosynthesis by a 9-(4-chlorophenyl) Analogue of Arachidonic Acid 1988 ·Journal of Pharmaceutical Sciences ·Chih Y. Ho,William Hageman,Richard J. Mohrbacher,David W. End	4
18	Antagonism by ETYA of the effects of leukotrienes on ileum and lung parenchymal strips independent of effects on arachidonic acid metabolism 1986 ·Prostaglandins ·William Hageman,Michael Rose,(unknown)	6
19	Cardiovascular profile of mixidine fumarate, a compound which attenuates myocardial chronotropic responses. 1980 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown),William Hageman,Henry I. Jacoby	5
20	Interaction of vasoactive agents and micro-emboli on the pulmonary circulation 1973 ·European Journal of Pharmacology ·William Hageman,(unknown),(unknown)	8

About William Hageman

William Hageman is a scholar working on Pharmacology, Endocrine and Autonomic Systems and Immunology and Allergy, having authored 33 papers that have together received 610 indexed citations. Recurring topics across this work include Neuroendocrine regulation and behavior (6 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Electrolyte and hormonal disorders (4 papers). The work is most often cited by research in Pharmacology (74 citations), Organic Chemistry (234 citations) and Pharmaceutical Science (28 citations). William Hageman has collaborated with scholars based in United States, Germany and Israel. Frequent co-authors include John A. Masucci, Gary W. Caldwell, Zhengyin Yan, David M. Ritchie, John B. Moore, Bruce E. Maryanoff, Keith T. Demarest, Sigmond G. Johnson, Dieter H. Klaubert and Sean Peng. Their work appears in journals such as Journal of the American Chemical Society, Analytical Biochemistry and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact